Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.68
NAS:EXEL's Cash-to-Debt is ranked lower than
73% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NAS:EXEL: 1.68 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:EXEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.34 Max: N/A
Current: 1.68
Equity-to-Asset 0.06
NAS:EXEL's Equity-to-Asset is ranked lower than
91% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:EXEL: 0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:EXEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.76  Med: 0.12 Max: 0.8
Current: 0.06
-0.76
0.8
Piotroski F-Score: 6
Altman Z-Score: 2.12
Beneish M-Score: 3.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -79.64
NAS:EXEL's Operating Margin % is ranked higher than
51% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NAS:EXEL: -79.64 )
Ranked among companies with meaningful Operating Margin % only.
NAS:EXEL' s Operating Margin % Range Over the Past 10 Years
Min: -893.86  Med: -145.27 Max: 30.91
Current: -79.64
-893.86
30.91
Net Margin % -128.59
NAS:EXEL's Net Margin % is ranked lower than
55% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:EXEL: -128.59 )
Ranked among companies with meaningful Net Margin % only.
NAS:EXEL' s Net Margin % Range Over the Past 10 Years
Min: -1069.42  Med: -120.52 Max: 26.14
Current: -128.59
-1069.42
26.14
ROA % -35.96
NAS:EXEL's ROA % is ranked lower than
55% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NAS:EXEL: -35.96 )
Ranked among companies with meaningful ROA % only.
NAS:EXEL' s ROA % Range Over the Past 10 Years
Min: -64.98  Med: -32.09 Max: 20.08
Current: -35.96
-64.98
20.08
ROC (Joel Greenblatt) % -3039.53
NAS:EXEL's ROC (Joel Greenblatt) % is ranked lower than
75% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:EXEL: -3039.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:EXEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6260.17  Med: -472.6 Max: 766.96
Current: -3039.53
-6260.17
766.96
3-Year Revenue Growth Rate -15.60
NAS:EXEL's 3-Year Revenue Growth Rate is ranked lower than
70% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:EXEL: -15.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:EXEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.3  Med: -0.4 Max: 25.7
Current: -15.6
-61.3
25.7
3-Year EBITDA Growth Rate -7.30
NAS:EXEL's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:EXEL: -7.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:EXEL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: -5.2 Max: 17.9
Current: -7.3
-44.8
17.9
3-Year EPS without NRI Growth Rate -4.20
NAS:EXEL's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NAS:EXEL: -4.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:EXEL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.1  Med: -6.9 Max: 16.1
Current: -4.2
-42.1
16.1
GuruFocus has detected 6 Warning Signs with Exelixis Inc $NAS:EXEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:EXEL's 10-Y Financials

Financials (Next Earnings Date: 2017-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EXEL Guru Trades in Q1 2016

Paul Tudor Jones 63,482 sh (New)
Jim Simons 1,008,919 sh (+82.99%)
Charles Brandes Sold Out
» More
Q2 2016

EXEL Guru Trades in Q2 2016

Joel Greenblatt 21,735 sh (New)
Steven Cohen 2,025,400 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 31,445 sh (-50.47%)
» More
Q3 2016

EXEL Guru Trades in Q3 2016

Jim Simons 1,868,450 sh (New)
Joel Greenblatt 130,059 sh (+498.39%)
Steven Cohen 4,132,900 sh (+104.05%)
Paul Tudor Jones 49,374 sh (+57.02%)
» More
Q4 2016

EXEL Guru Trades in Q4 2016

Joel Greenblatt 422,461 sh (+224.82%)
Steven Cohen Sold Out
Jim Simons 1,310,510 sh (-29.86%)
Paul Tudor Jones 25,973 sh (-47.40%)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:UTHR, NAS:IONS, NAS:ACAD, NAS:ARIA, NAS:ALKS, NAS:JAZZ, NAS:ALNY, NAS:TECH, NAS:SGEN, NAS:BLUE, NAS:RARE, OTCPK:GLPGF, NAS:CBPO, NAS:ICPT, OTCPK:BTGGF, NAS:CLVS, NAS:SAGE, OTCPK:ABCZF, NAS:LGND, NAS:NKTR » details
Traded in other countries:EX9.Germany,
Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.

Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.

Ratios

vs
industry
vs
history
Forward PE Ratio 357.14
EXEL's Forward PE Ratio is ranked lower than
99% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. EXEL: 357.14 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 278.08
EXEL's Price-to-Owner-Earnings is ranked lower than
92% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. EXEL: 278.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EXEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.09  Med: 90.25 Max: 296.41
Current: 278.08
4.09
296.41
PB Ratio 193.66
EXEL's PB Ratio is ranked lower than
99% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. EXEL: 193.66 )
Ranked among companies with meaningful PB Ratio only.
EXEL' s PB Ratio Range Over the Past 10 Years
Min: 2.53  Med: 16.45 Max: 927.5
Current: 193.66
2.53
927.5
PS Ratio 42.03
EXEL's PS Ratio is ranked lower than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. EXEL: 42.03 )
Ranked among companies with meaningful PS Ratio only.
EXEL' s PS Ratio Range Over the Past 10 Years
Min: 1.64  Med: 8.65 Max: 47.25
Current: 42.03
1.64
47.25
Price-to-Free-Cash-Flow 59.59
EXEL's Price-to-Free-Cash-Flow is ranked lower than
75% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. EXEL: 59.59 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EXEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.31  Med: 29.15 Max: 63.52
Current: 59.59
3.31
63.52
Price-to-Operating-Cash-Flow 58.46
EXEL's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. EXEL: 58.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EXEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.26  Med: 28.45 Max: 62.32
Current: 58.46
3.26
62.32
EV-to-EBIT -56.28
EXEL's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. EXEL: -56.28 )
Ranked among companies with meaningful EV-to-EBIT only.
EXEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.6  Med: -5.7 Max: 35.5
Current: -56.28
-53.6
35.5
EV-to-EBITDA -56.86
EXEL's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. EXEL: -56.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -54.2  Med: -6 Max: 28.1
Current: -56.86
-54.2
28.1
Current Ratio 2.09
EXEL's Current Ratio is ranked lower than
74% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. EXEL: 2.09 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.37 Max: 9.35
Current: 2.09
0.84
9.35
Quick Ratio 2.07
EXEL's Quick Ratio is ranked lower than
70% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. EXEL: 2.07 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.37 Max: 9.35
Current: 2.07
0.84
9.35
Days Inventory 169.76
EXEL's Days Inventory is ranked lower than
64% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. EXEL: 169.76 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s Days Inventory Range Over the Past 10 Years
Min: 234.13  Med: 470.86 Max: 471.76
Current: 169.76
234.13
471.76
Days Sales Outstanding 268.88
EXEL's Days Sales Outstanding is ranked lower than
94% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. EXEL: 268.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.51  Med: 33.29 Max: 82.11
Current: 268.88
4.51
82.11
Days Payable 252.88
EXEL's Days Payable is ranked higher than
88% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. EXEL: 252.88 )
Ranked among companies with meaningful Days Payable only.
EXEL' s Days Payable Range Over the Past 10 Years
Min: 599.84  Med: 1145.74 Max: 3050.92
Current: 252.88
599.84
3050.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
EXEL's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. EXEL: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -204.5  Med: -11.9 Max: -1.3
Current: -7.5
-204.5
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 4.87
EXEL's Price-to-Median-PS-Value is ranked lower than
94% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. EXEL: 4.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.08 Max: 4.14
Current: 4.87
0.23
4.14
Earnings Yield (Greenblatt) % -1.80
EXEL's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. EXEL: -1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 12.5 Max: 17.5
Current: -1.8
2.8
17.5

More Statistics

Revenue (TTM) (Mil) $123.8
EPS (TTM) $ -0.69
Beta2.65
Short Percentage of Float9.52%
52-Week Range $3.55 - 23.49
Shares Outstanding (Mil)286.46

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 179 317 494 778
EPS ($) -0.43 0.06 0.29 1.09
EPS without NRI ($) -0.43 0.06 0.29 1.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:EXEL

Headlines

Articles On GuruFocus.com
Top Performing Contest Portfolios from 2016 Jan 17 2017 
7 Stocks Outperforming the Market Jan 12 2017 
Why You Should Be Using the Altman Z-Score Dec 18 2016 
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 

More From Other Websites
Why Earnings Season Could Be Great for Exelixis (EXEL) Feb 24 2017
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store? Feb 22 2017
Patterson Companies (PDCO) Q3 Earnings: What's in Store? Feb 21 2017
Forget Alexion, Buy these 4 Biotech Stocks Instead Feb 20 2017
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards? Feb 20 2017
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or... Feb 17 2017
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint? Feb 17 2017
Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on... Feb 17 2017
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia... Feb 14 2017
Forget Gilead, Buy These 5 Biotech Stocks Instead Feb 13 2017
Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure... Feb 10 2017
Exelixis (EXEL) Shares March Higher, Can It Continue? Feb 10 2017
Harry Boxer’s stocks to watch: biotechnology and technology Feb 09 2017
Buy 4 Stocks Riding High on Superb Earnings Acceleration Feb 09 2017
5 Drug Stocks Poised to Beat Earnings Estimates in Q4 Feb 09 2017
Four Biotech Stocks Breaking Out Feb 08 2017
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma Feb 08 2017
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis... Feb 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)